Moberg Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOB.ST research report →
Companywww.mobergpharma.se
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
- CEO
- Jonas Ekblom
- IPO
- 2011
- Employees
- 10
- HQ
- Bromma, SE
Price Chart
Valuation
- Market Cap
- $502.91M
- P/E
- -19.42
- P/S
- 34.46
- P/B
- 0.75
- EV/EBITDA
- -11.58
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 57.38%
- Op Margin
- -188.80%
- Net Margin
- -176.32%
- ROE
- -3.83%
- ROIC
- -4.13%
Growth & Income
- Revenue
- $13.54M · 37.99%
- Net Income
- $-27,236,000 · 89.32%
- EPS
- $-0.58 · 91.39%
- Op Income
- $-27,997,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $14.12
- 52W Low
- $7.53
- 50D MA
- $10.85
- 200D MA
- $9.52
- Beta
- 0.64
- Avg Volume
- 101.88K
Get TickerSpark's AI analysis on MOB.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MOB.ST Coverage
We haven't published any research on MOB.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MOB.ST Report →